Mayuko Miki, Sachiko Inubushi, Qinghong Han, Shotaro Inoue, Tomonari Kunihisa, Hirokazu Tanino, Robert M Hoffman. Efficacy of Methionine Restriction and the PARP-inhibitor Olaparib and Their Combination on BRCA1 Mutant and Wild-type Triple-negative Breast Cancer Cell Lines. Anticancer research. 2025. 45. 4. 1367-1372
Sachiko Inubushi, Tomonari Kunihisa, Marina Kuniyasu, Shotaro Inoue, Mayuko Yamamoto, Yuji Yamashita, Mayuko Miki, Sachiko Mizumoto, Motoi Baba, Robert M Hoffman, et al. Serum Exosomes Expressing CD9, CD63 and HER2 From Breast-Cancer Patients Decreased After Surgery of the Primary Tumor: A Potential Biomarker of Tumor Burden. Cancer genomics & proteomics. 2024. 21. 6. 580-584
Tomonari Kunihisa, Sachiko Inubushi, Hirokazu Tanino, Robert M Hoffman. Induction of the DNA-Repair Gene POLQ only in BRCA1-mutant Breast-Cancer Cells by Methionine Restriction. Cancer genomics & proteomics. 2024. 21. 4. 399-404
Yoshimasa Kosaka, Naoko Minatani, Yoko Tanaka, Akiko Shida, Mariko Kikuchi, Hiroshi Nishimiya, Mina Waraya, Hiroshi Katoh, Takeo Sato, Norihiko Sengoku, et al. Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. Molecular and clinical oncology. 2018. 9. 5. 566-574
Risk analysis for chemotherapy induced nausea and vomiting (CINV) in patients receiving FEC100 treatment
(SAN ANTONIO BREAST CANCER SYMPOSIUM 43rd Annual SABCS 2018)
Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4:J-CAT trial)
(SAN ANTONIO BREAST CANCER SYMPOSIUM 43rd Annual SABCS 2018)
BRCAness as a prognostic marker in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: A multicenter retrospective study
(SAN ANTONIO BREAST CANCER SYMPOSIUM 43rd Annual SABCS 2018)